Home
overview

Metabolic diseases affect millions of sufferers worldwide and are having an increasingly negative impact upon the health of our society as a whole. According to recent figures, type II diabetes affects more than 135 million people whilst those meeting the criteria set for obesity reaches 300 million respectively. Needless to say pharmaceutical companies are hot on the pursuit of lucrative solutions to aid in the prevention and/or management of major metabolic syndromes.

Following a series of well received events for the industry, SMi would like to announce it’s inaugural ‘Metabolic Diseases Forum’ designed specifically to uncover the latest market trends, challenges and emerging therapies. Understand the aetiology and epidemiology of key metabolic disorders whilst discovering new targets for drug discovery and hear reports from current and future clinical trials, including real clinical data, while we assess the clinical outlook for metabolic disease 2006 an beyond!

Enjoy our streamed sessions as we take a closer look at key disease specific drugs on track towards regulatory approval and market release. Learn how to complete your clinical trials whilst satisfying regulatory requirements and discover what is really expected in a new product application and how to achieve it. Join us and a host of leading experts including representatives from Sanofi-Aventis, Eli Lilly, Novo Nordisk, Pfizer, Amylin and many others at SMi’s Metabolic Diseases Forum 2006!

Our exceptional speaker line-up includes:

  • Dr Michael Mark, Vice President, Metabolic Diseases Research, Boehringer-Ingelheim
  • Dr Douglas Greene, Vice President, Regulatory Development, Sanofi-Aventis 
  • Dr David Maggs, Vice President, Medical Affairs, Amylin Pharmaceuticals 
  • Dr Howard Foyt, Vice President, Clinical Development, Metabasis Therapeutics 
  • Dr Satish Singh, Expert Clinical Assessor, Medicine & Healthcare products Regulatory Agency (MHRA)
  • Dr Richard Palmer, Chief Executive Officer & Research & Development Director, Alizyme
  • Dr Nancy Thornberry, Executive Director, Metabolic Disorders, Merck Research Laboratories
  • Dr Richard Carr, Senior Director, Novo Nordisk
  • Dr Uwe Gudat, Global Brand Medical Director, Dyslipidemia & Diabetes, Novartis
  • Dr Alex De Paoli, Director, Global Development, Amgen
  • Dr Cristina Rondinone, Director, Research, Metabolic Diseases, Hoffmann-La Roche
  • Dr Andrew Swick, Director, Cardiovascular & Metabolic Diseases, Pfizer

Attend this industry specific forum to guarantee you hear international and expert perspectives on:

  • THE METABOLIC DISEASES MARKET: Hear discussion on the latest trends, challenges and emerging therapeutics together with a view to addressing current unmet clinical needs
  • REGULATORY GUIDELINES AND IMPLICATIONS FOR INDUSTRY: Can new regulatory standards reduce the time and cost of product development? Hear from the UK’s MHRA as they explain what can be expected in a new product application and how to achieve approval
  • NEXT GENERATION DRUGS: Explore the current and future targets for treating diabetes and obesity with novel approaches such as RNAi, MCH1R and pathogenic pathways with relevant molecular targets for drug discovery
  • TRANSLATIONAL MEDICINE: Understand how best to predict human efficacy based on preclinical data
  • ASSESSING CLINICAL DRUG DEVELOPMENT: Listen to the experts as they review key drug developments over the past year with a focus on challenges, limitations and how they can be overcome
  • CASE STUDIES: Hear from major industry players as they discuss real clinical data and what it means. Plus choose from two streams focussing on current and future therapies to alleviate diabetes and obesity
  • GOING TO MARKET: Follow the progress of Lilly/Amylin’s Byetta – why has this drug become so successful despite not being directly marketed to consumers? Hear from the experts as they discuss how best to launch a drug for major metabolic disease
  • THE METABOLIC SYNDROME: Attend our half-day Executive Briefing to understand why the metabolic syndrome is regarded as an unmet therapeutic need and a major commercial opportunity for many pharmaceutical companies

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

9:50 REGULATORY ISSUES IN THE DEVELOPMENT OF DRUGS FOR DIABETES AND METABOLIC DISORDERS

Satish Singh

Satish Singh, Expert Clinical Assessor, MHRA

  • Metabolic Syndrome
  • Diabetes
  • Obesity - Adults
  • - Children/adolescents

  • Atherosclerosis
  • Conduct of trials/requirements for regulatory approval
  • 10:30 Morning Coffee

    11:00 DEVELOPING NOVEL TREATMENTS FOR AN EMERGING EPIDEMIC: TYPE II DIABETES

    Uwe Gudat

    Uwe Gudat, Global Brand Medical Director, Dyslipidemia & Diabetes, Novartis

  • Incretins as endogenous turbochargers
  • Augmenting the incretin effect by inhibiting DPP-IV
  • DPP-IV inhibitors - a crowded field?
  • Demonstrated clinical efficacy of DPP-IV inhibition
  • The therapeutic potential of DPP-IV inhibition
  • 12:20 Networking Lunch

    14:40 CASE STUDY: CETILISTAT - AN INVESTIGATIONAL DRUG FOR OBESITY AND CO-MORBIDITIES

    Richard Palmer

    Richard Palmer, Chief Executive Officer & Research & Development Director, Alizyme

  • Target profile for an obesity drug in today’s environment
  • Cetilistat: evidence of efficacy and tolerability in obese adults?
  • Efficacy in obese diabetics
  • Superior tolerability profile and patient compliance
  • Challenges for the future in a global problem
  • 14:40 DPP-4 INHIBITION FOR THE TREATMENT OF TYPE 2 DIABETES

    Nancy Thornberry

    Nancy Thornberry, Executive Director, Metabolic Disorders, Merck & Co Inc

  • Overview of DPP-4 Biology
  • Discovery of Sitagliptin
  • Preclinical profile of Sitagliptin, including effects on beta cells
  • Clinical studies with Sitaglipin
  • Profile/potential advantages of Januvia vs current therapy
  • 15:20 Afternoon Tea

    15:40 MB06322 (CS-917)

    Howard Foyt

    Howard Foyt, Vice President, Clinical Development, Metabasis Therapeutics Inc

  • Overview of gluconeogenesis in Type 2 diabetes mellitus
  • Inhibition of fructose-1,6-bisphosphatase as a means to decrease hepatic glucose output
  • Structure-guided drug design strategy in the discovery of CS-917
  • Review of animal models and clinical data showing the utility of CS-917 in providing long term glycemic control in the full spectrum of T2DM patients in the absence of weight gain
  • 15:40 SIBUTRAMINE - A 20:20 HINDSIGHT PERSPECTIVE ON ITS APPROVAL AND USE AS A DRUG TO TREAT OBESITY AND RELATED CO-MORBIDITIES

    David Heal

    David Heal, Director, Renasci Consultancy Ltd

  • The marketing approval process
  • Efficacy in long-term obesity management
  • Beneficial effects of sibutramine in metabolic syndrome
  • The Sibutramine Cardiovascular OUTcome (SCOUT) trial
  • 16:20 AMYLIN ANALOGUES: FOR THE TREATMENT OF DIABETES, OBESITY AND CARDIOVASCULAR DISEASE

    Matthew Wintle

    Matthew Wintle, Director, Medical Affairs Programmes, Amylin Pharmaceuticals Inc

  • Amlyin analogues – mechanism of action
  • Hear an update on the preclinical and clinical development of pramlintide for obesity
  • Effect on patient weight loss/weight stabilisation
  • Gaining FDA approval for Type I and Type II diabetes –best practice advice
  • Case study: Symlin®
  • Filing for European regulatory approval: Pramlintide and it’s submission preparation to the European authorities
  • Byetta – why has this drug become so successful despite not being marketed directly to consumers?
  • Are there any plans for the non-diabetic study of this drug?
  • Seeking approval for the expanded use of BYETTA® - current status
  • Best practice advice – launching your product
  • 16:20 ASSESSING THE LATEST IN CLINICAL DEVELOPMENT FOR OBESITY RELATED METABOLIC DISORDERS

  • A classic CB1 antagonist?
  • Review of clinical data – results from phase III trials and beyond
  • Comparing rimonabant at doses of 5mg and 20mg with placebo – what do we learn?
  • Can Rimonabant be well tolerated for long-term use?
  • The phase IIIb trial programme for Rimonabant – what indications are available for studies in patients with diabetes, dyslipidaemia and cardiovascular disease?
  • Achieving regulatory approval
  • Going to market – key strategies for success
  • Douglas Greene

    Douglas Greene, Vice President, Regulatory Affairs, Sanofi-Aventis

    17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Elena Sebokova

    Elena Sebokova, Disease Area Head, Metabolic Diseases, F. Hoffmann-La Roche

    9:10 ADDRESSING UNMET NEEDS

    Simon Westbrook

    Simon Westbrook, Associate Research Fellow, Cardiovascular & Metabolic Diseases, Pfizer

  • Assessing the need for effective anti-obesity/anti-diabetic drugs
  • What is the profile of an ideal therapy?
  • Novel approaches to drug discovery
  • Target-based therapies - what exciting treatments are on the horizon?
  • Combination therapies - will they be required?
  • 9:50 HOW TO STUDY NEW ANTI-DIABETIC AGENTS?

    Richard Carr

    Richard Carr, Senior Director, Novo Nordisk

  • How to overcome the challenges in developing novel anti-diabetic therapies?
  • Clinical evaluations and comparative studies
  • Novel concepts – anti-diabetic agents with cardioprotective mechanisms
  • New methods of improving clinical development for your organisation
  • Future prospects
  • 10:30 Morning Coffee

    11:00 ADVANCES IN CNS ANTI-OBESITY THERAPEUTICS

    Alison Strack

    Alison Strack, Senior Research Fellow, Merck & Co Inc

  • CNS pathways regulating feeding and energy expenditure
  • Opposing regulation by melanocortin and NPY in the hypothalamus
  • Is grehlin a player?
  • Combinatorial effects on energy homeostasis
  • 11:40 NEXT GENERATION DRUGS

    James H. Harwood

    James H. Harwood, Principle Research Investigator, Pfizer

  • Current and upcoming targets for treating diabetes and obesity
  • Novel approaches that target multiple risk factors simultaneously
  • Options for treating the cardiovascular risk of patients with metabolic syndrome
  • Case examples
  • Challenges, benefits and limitations of these targets
  • The future outlook
  • 12:20 Networking Lunch

    13:50 MCH1R AS AN IDEAL TARGET FOR ANTI-OBESITY THERAPY

  • Understanding MCH biology in animals
  • MCH signalling influences food intake
  • Key differences in MCH receptors between animals and humans
  • Opportunities to address obesity in humans through manipulation of MCHR1
  • Alex De Paoli

    Alex De Paoli, Director, Global Development, Amgen

    Riccardo Perfetti

    Riccardo Perfetti, Associate Director, Medical Sciences, Amgen

    14:30 NEUROENDOCRINE AND METABOLIC FACTORS CONTROLLING APPETITE, OBESITY AND INSULIN RESISTANCE

    Anita van den Hoek

    Anita van den Hoek, Research Scientist, Vascular and Metabolic Disease Research Department, TNO Prevention and Health

  • Regulation of appetite and obesity by NPY and POMC pathway
  • Balance between NPY and POMC regulates insulin sensitivity
  • NPY and hepatic insulin resistance via sympathetic nervous system
  • Role of peripheral hormones in central regulation of appetite and insulin sensitivity
  • PYY redirects substrate utilization towards fat oxidation
  • 15:10 Afternoon Tea

    15:40 ALTERING THE EXPRESSION OF HEPATIC GENES INVOLVED IN LIPID METABOLISM IN ZDF RATS

    Yin Liang

    Yin Liang, Principal Scientist, Metabolic Research Team, Johnson & Johnson

  • In obese-associated Type II diabetic rodent models, topiramate (TPM) reduced the body weight gain, improved insulin sensitivity and enhanced insulin release
  • The molecular mechanisms of TPM anti-obesity and anti-diabetic effects remain unknown
  • DNA microarray data revealed that TPM treatment altered hepatic gene expression of metabolic enzymes and signaling regulatory proteins involved in energy metabolism
  • These gene expressions were independent of food intake as demonstrated by pair-feeding
  • TPM regulates hepatic expression of genes involved in lipid metabolism, which could be part of the mechanism by which TPM reduces plasma triglyceride levels and improves insulin sensitivity in obese-diabetic rodents
  • 16:20 THE GHRELIN PATHWAY IN THE CONTROL OF GLUCOSE HOMEOSTASIS

    Peter DiStefano

    Peter DiStefano, Chief Scientific Officer, Elixir Pharmaceuticals, Inc.

  • Ghrelin is a gut-derived peptide that controls feeding and growth hormone release
  • Recent studies have shown that ghrelin/ghrelin receptor knockout mice are resistant to diet-induced obesity
  • These mice also have favourable metabolic parameters when faced with a metabolic stressor diet
  • Small molecule ghrelin antagonists have been generated that are potent (nM), selective and safe for in vivo use
  • Treatment with ghrelin antagonists improves glucose homeostasis in diet-stressed mice
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    An Overview of the Metabolic Syndrome
    Workshop

    An Overview of the Metabolic Syndrome

    Hilton London Kensington
    4th October 2006
    London, United Kingdom

    Hilton London Kensington

    179-199 Holland Park Avenue
    London W11 4UL
    United Kingdom

    Hilton London Kensington

    Expect a warm welcome the moment you arrive at Hilton London Kensington. We’re located in the leafy district of Holland Park, 30 minutes from Heathrow Airport, with excellent transport links into Central London and three different tube lines nearby. Step inside the hotel and you’ll find stylish rooms and suites, fantastic dining and first-class facilities for business and recreation — everything you need for a remarkable stay in the capital.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.